cas 2105905-46-0|| where to buy 4,6-dichloro-1H-pyrazolo[3,4-b]pyridine

Nom du produit:4,6-dichloro-1H-pyrazolo[3,4-b]pyridine

IUPAC Name:4,6-dichloro-1H-pyrazolo[3,4-b]pyridine

Unité d'emballage	Stock disponible	Prix($)
CM325579-1g	in stock	Ōĳ
CM325579-5g	in stock	ĳŌǸ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2105905-46-0 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2105905-46-0; Formule moléculaire:C6H3Cl2N3; Point de fusion:-; Code SMILES:ClC1=CC(Cl)=C2C(NN=C2)=N1; Densité:

: Numéro de catalogue:CM325579; Poids moléculaire:188.01; Point d'ébullition:; N° Mdl:; Stockage:Keep in a tight container and store at 2°C~8°C for long term and which can be kept in a tight container at ambient temperature f

: Pyrazolopyridines; Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.

: Quemliclustat; Data from a phase 1b study of Quemliclustat-based regimens showed promising overall survival in treatment-naïve metastatic pancreatic cancer. Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone.
Quemliclustat is an investigational, potent and selective small molecule CD73 inhibitor. CD73 is the primary enzymatic producer of immunosuppressive adenosine in the tumor microenvironment, and high CD73 expression is associated with significantly poorer prognosis in several tumor types. Quemliclustat has been shown to block the production of adenosine. Once the immunosuppressive effects of adenosine are removed, activation of antitumor immune cells may be restored, resulting in cancer cell death.